Regencell Bioscience (RGC) Stock Price, News & Analysis

Company Overview

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Key Stats

• Today's Range: $12.41 to $13.82
• 50-Day Range: $10.36 to $22.99
• 52-Week Range: $0.09 to $83.60
• Volume: 289,311 shs
• Average Volume: 283,458 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Regencell Bioscience Stock Analysis - MarketRank™

Regencell Bioscience scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Regencell Bioscience.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Regencell Bioscience has a P/B Ratio of 642.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.89% of the float of Regencell Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Regencell Bioscience has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Regencell Bioscience has recently increased by 0.44%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Regencell Bioscience does not currently pay a dividend.

Dividend Growth

Regencell Bioscience does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.89% of the float of Regencell Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Regencell Bioscience has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Regencell Bioscience has recently increased by 0.44%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 5 people have searched for RGC on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Regencell Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -85% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Regencell Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.00% of the stock of Regencell Bioscience is held by insiders.

Percentage Held by Institutions

Only 0.13% of the stock of Regencell Bioscience is held by institutions.

RGC Stock Analysis - Frequently Asked Questions

How have RGC shares performed this year?

Regencell Bioscience's stock was trading at $63.35 at the start of the year. Since then, RGC shares have decreased by 79.7% and is now trading at $12.84.

When did Regencell Bioscience's stock split?

Regencell Bioscience shares split on Monday, June 16th 2025.The 38-1 split was announced on Monday, June 2nd 2025. The newly minted shares were issued to shareholders after the closing bell on Sunday, June 15th 2025. An investor that had 100 shares of stock prior to the split would have 3,800 shares after the split.

When did Regencell Bioscience IPO?

Regencell Bioscience (RGC) raised $22 million in an IPO on Friday, July 16th 2021. The company issued 2,300,000 shares at $8.50-$10.50 per share.

Who are Regencell Bioscience's major shareholders?

Regencell Bioscience's top institutional shareholders include Geode Capital Management LLC, Squarepoint Ops LLC, Squarepoint Ops LLC and BNP Paribas Financial Markets.

How do I buy shares of Regencell Bioscience?

Shares of RGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/05/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Medicinal Chemicals
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RGC
• Previous Symbol: NASDAQ:RGC
• CIK: 1829667
• Web: N/A
• Phone: 852 2155 0823
• Fax: 852-2155-0853
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.02 per share
• Price / Book: 642.00

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: 2.16